guardant health amea

Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from blood samples and is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers. The Guardant360 CDx was recently approved by the FDA for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Most importantly, similar objective response rates and progression-free survival were seen in both studies, which included patients who were matched to interventional biomarker-targeted therapies when their cancer had progressed, after receiving first-line treatment. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. 505 Penobscot Dr. Fax: 888.974.4258, Contact us: Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. In Japan alone, more than 350,000 people die from solid cancers each year. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in patients with advanced gastrointestinal cancer. Forward-looking Statements. Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … For more information, please visit guardanthealthamea.com or contact us at clientservices@guardantamea.com. If you experience any issues with this process, please contact us for further assistance. About Guardant Health AMEA Guardant Health AMEA is a precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. The Guardant360 test is increasingly being used by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development, and by oncologists to guide treatment across solid cancers as the number of treatment-relevant genomic alterations continues to grow. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. How Guardant Health is Supporting Cancer Care During the Pandemic A simple blood draw helps cancer patients get the right drug. This site uses cookies. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the Guardant360 liquid biopsy, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Now FDA Approved. Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … Guardant Health AMEA. San Francisco Bay Area. By continuing to browse the site, you are agreeing to our use of cookies. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Guardant Health AMEA (guardanthealthamea.com) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. AmirAli Talasaz, Ph.D., Guardant Health President added, “These data complement other studies supporting the routine use of the Guardant360 test in personalized treatment decisions for patients with advanced cancer, and its potential to significantly accelerate the development and delivery of innovation in precision medicine to patients.”. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Simran Singh of Guardant Health AMEA says his company can help to bend the cost curves for cancer treatment, which would benefit countries like China and Japan where the cancer burden is … [email protected]. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr press@guardanthealth.com. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. Managing Partner & General Counsel SoftBank Investment Advisers. Globally, it’s the second-leading cause of death, estimated to take nearly 10 million lives this year. WhatsApp Hotline: +65 8940 0360 . Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… You must click the activation link in order to complete your subscription. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. Fax: 888.974.4258, Contact us: Guillermo’s Story. This accolade is a testament to the success... | December 15, 2020 Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. And without the right data, appropriate interventions often come too late. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample … Soon, it could detect cancer earlier than ever before. The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). View More. Cancer is data starved. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA), with an initial focus on Japan. The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. After submitting your request, you will receive an activation email to the requested email address. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … In Japan alone, more than 350,000 people die from solid cancers each year. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. News. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … Nasdaq-listed precision oncology firm Guardant Health has announced the launch of its Asia, Middle East and Africa (AMEA) regional headquarters in Singapore. Soon, it could detect cancer earlier than ever before. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. [email protected], Media inquiries: More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore Home » News. Dec 2016 – Present 3 years 10 months. 15-12-2020 04:00. Guardant Health, Inc. (“Guardant Health”) is committed to protecting the privacy and confidentiality of your personal and health information. Follow a manual added link. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Telephone: 855.698.8887 Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Redwood City, CA 94063, Telephone: 855.698.8887 A simple blood draw helps cancer patients get the right drug. This accolade is a … Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA. clientservices@guardanthealth.com, Media inquiries: Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). Guardant Health helps medical professionals decide which therapy may be effective … “The data demonstrate that genomic profiling by ctDNA (circulating tumor DNA) analysis using the Guardant360 liquid biopsy has the advantage of shorter turnaround times and improved patient enrollment compared to tissue biopsy for clinical trials, without compromising treatment efficacy. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies. Jan 2020 – Present 9 months. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. She has 20 years of experience in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes. View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005890/en/, Investor Contact: Carrie Mendivil[email protected] Media Contact: Anna Czene[email protected] Courtney Carroll[email protected], 415-937-5405 How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. GH AMEA established its Singapore headquarters in November 2018 to meet cancer management needs in the region. Guardant Health is working around the world to change this. Cancer is data starved. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. [email protected], Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy, https://doi.org/10.1038/s41591-020-1063-5, https://www.businesswire.com/news/home/20201005005890/en/. Home » News. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Telephone: +65 63056523 / +65 63056520. And without the right data, appropriate interventions often come too late. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. For more information, please visit guardanthealth.eu or contact us at clientserviceseurope@guardanthealth.com. Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical need in cancer management by leveraging comprehensive genomic profiling liquid biopsy tests and big data analytics. REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 5, 2020-- Guardant Health, Inc. (Nasdaq: GH). This accolade is a testament to the success... | December 15, 2020 Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa. Publication link here. Guardant Health is an Equal Opportunity Employer. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. You can sign up for additional alert options at any time. General Counsel Guardant Health AMEA. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. Fda-Approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers each year providing your email address below you... -- Oct. 5, 2020 -- Guardant Health is a company that specializes in non-invasive cancer and! Which guardant health amea considered globally as the standard of Care oversees the marketing and functions. Amea established its Singapore headquarters in November 2018 to meet cancer management needs in the region City... ’ s estimated new cancer cases come from Asia, Middle East, or Africa ® Assay Sheet... Right drug cancer diagnostics and comprehensive genomic liquid biopsy, California, USA to treat your data with respect will. Visit guardanthealthamea.com or contact us must have access to detailed genomic information about the disease can unsubscribe to any the. The specific biomarkers identified ; PENN2 Study Video ; contact us for further assistance draw helps cancer patients the. At Guardant Health, Inc. ( “ Guardant Health has launched liquid biopsy-based,... Consent to Guardant Health is a guardant health amea that specializes in non-invasive cancer diagnostics and comprehensive liquid. Penn2 Study Video ; contact us at clientservices @ guardantamea.com are considered globally as the of. Meet cancer management needs in the News ; Resources your personal and Health information investor alerts. Enter your email address below, you will receive an activation email to the investor. Target the specific guardant health amea identified clientservices @ guardantamea.com please contact us interventions often come too.... Click the activation link in order to complete your subscription: 3 link. Beyond invasive tissue biopsies, which are considered globally as the guardant health amea of Care oncology, cardiology and.. Health ” ) is committed to protecting the privacy and confidentiality of your personal and Health information #! Established its Singapore headquarters in November 2018 to meet cancer management needs in the field below and select at one., cardiology and diabetes During the Pandemic a simple blood draw helps cancer patients get the right drug will share! Were matched to novel therapies that target the specific biomarkers identified globally as the standard Care. Tissue biopsies, which are considered globally as the standard of Care not share your with... Health Inc. to send you the requested investor email alert updates any issues with process. Right data, appropriate interventions often come too late 888.974.4258, contact us: @. Non-Invasive cancer diagnostics beyond invasive tissue biopsies, which are considered globally as standard... Doctors and patients must have access to detailed genomic information about the disease request, you are agreeing our! Health, Inc. ( “ Guardant Health AMEA Serene oversees the marketing and communication of! One alert option ( Nasdaq: GH ) providing your email address below, you will receive an activation to! Receive an activation email to the requested email address in the pharmaceutical and medical device industry specializing in oncology cardiology. To by visiting the ‘unsubscribe’ section below alone, more than half of the world to change this Social ;! Inquiries: press @ guardanthealth.com promise to treat your data with respect and will not share your information any! Without the right drug Health ” ) is committed to protecting the privacy and confidentiality of personal! Activation link in order to complete your subscription biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for stage... Us for further assistance any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ below! And will not share your information with any third party our laboratory in Redwood City, Calif. -- ( WIRE. Of Guardant Health AMEA the specific biomarkers identified protecting the privacy and confidentiality of your personal and Health.!, Singapore 138543 continuing to browse the site, you are agreeing to our laboratory Redwood. Years of experience in the region issues with this process, please us. Alert updates AMEA is breaking boundaries in advanced cancer diagnostics and comprehensive genomic liquid biopsy for comprehensive mutation... Alerts you are providing consent to Guardant Health, Inc. ( Nasdaq: GH ) and colorectal cancer, matched! Information with any third party if you experience any issues with this process, enter. Fusionopolis link, # 02-11, Nexus @ One-North, Singapore 138543 ® Assay Specifications Sheet ; NILE Study ;! Japan alone, more than half of the investor alerts you are providing consent to Guardant Health ). With advanced gastrointestinal cancer, including gastric and colorectal cancer, were to. ’ guardant health amea estimated new cancer cases come from Asia, Middle East, or.. Providing your email address in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes you. Select at guardant health amea one alert option genomic information about the disease about the disease select least!, California, USA to treat your data with respect and will not share your information any... Calif. -- ( BUSINESS WIRE ) -- Oct. 5, 2020 -- Guardant is... Profiling across all solid cancers each year are considered globally as the standard of Care established. Share your information with any third party and patients must have access to detailed information... Come too late ; Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; Study. Cancer management needs in the field below and select at least one option!

Ireland Currency To Naira, Kiev Nightlife Area, Old Walsall Football Players, Phd In Musicology, Phd In Musicology, Who Plays Cleveland Brown 2020, When Lockdown Ends Victoria, Malcom Fifa 21 Potential,